These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 5071041)

  • 1. Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate.
    Beckett RB; Weiss R; Stitzel RE; Cenedella RJ
    Toxicol Appl Pharmacol; 1972 Sep; 23(1):42-53. PubMed ID: 5071041
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of serum triglyceride lowering to changes in hepatic composition induced by different classes of drugs.
    Dalton C; Hope WC; Hope HR; Sheppard H
    Biochem Pharmacol; 1974 Feb; 23(3):685-96. PubMed ID: 4150813
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat.
    Berman JS; Hiley CR; Wilson AC
    Br J Pharmacol; 1983 Mar; 78(3):533-41. PubMed ID: 6839062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of hypolipidemic drugs in the prevention of an orotic acid fatty liver.
    Elwood JC; Richert DA; Westerfeld WW
    Biochem Pharmacol; 1972 Apr; 21(8):1127-34. PubMed ID: 5034198
    [No Abstract]   [Full Text] [Related]  

  • 5. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
    Reddy J; Svoboda D; Azarnoff D
    Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatic effect of two hypolipidemic drugs in rats.
    Magnusson G; Magnusson O
    Exp Pathol (Jena); 1977; 13(2-3):180-7. PubMed ID: 913535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofibrate and nafenopin (SU-13437): effects on plasma clearance and tissue distribution of chylomicron triglyceride in the dog.
    Cenedella RJ
    Lipids; 1972 Oct; 7(10):644-52. PubMed ID: 4635558
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of hypolipidemic drugs, nafenopin and clofibrate, on the concentration of ligandin and Z protein in rat liver.
    Fleischner G; Meijer DK; Levine WG; Gatmaitan Z; Gluck R; Arias IM
    Biochem Biophys Res Commun; 1975 Dec; 67(4):1401-7. PubMed ID: 812503
    [No Abstract]   [Full Text] [Related]  

  • 9. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
    Moody DE; Reddy JK
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):501-10. PubMed ID: 4445568
    [No Abstract]   [Full Text] [Related]  

  • 10. On the mode of action of lipid-lowering agents. VII. In vivo inhibition and reversible binding of hepatic acetyl coenzyme A carboxylase by hypolipidemic drugs.
    Maragoudakis ME; Hankin H; Wasvary JM
    J Biol Chem; 1972 Jan; 247(2):342-7. PubMed ID: 5009689
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential effects of benzodioxane, chroman, and dihydrobenzofuran analogs of clofibrate on various parameters of hepatic drug metabolism.
    Lewis NJ; Feller DR; Poochikian GK; Witiak DT
    J Med Chem; 1974 Jan; 17(1):41-5. PubMed ID: 4808468
    [No Abstract]   [Full Text] [Related]  

  • 12. Two hypolipidemic peroxisome proliferators increase the number of lamellar bodies in alveolar cells type II of the rat lung.
    Fringes B; Reith A
    Exp Mol Pathol; 1988 Apr; 48(2):262-71. PubMed ID: 3258252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evaluation of the hypolipidemic effects in man of a new phenolic ether (Su-13437, CIBA).
    Best MM; Duncan CH
    J Atheroscler Res; 1969; 10(1):103-6. PubMed ID: 5380895
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver.
    Gerbracht U; Bursch W; Kraus P; Putz B; Reinacher M; Timmermann-Trosiener I; Schulte-Hermann R
    Carcinogenesis; 1990 Apr; 11(4):617-24. PubMed ID: 1691053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
    Tuchweber B; Salas M
    Arch Toxicol; 1978 Dec; 41(3):223-32. PubMed ID: 736793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.
    Orton TC; Parker GL
    Drug Metab Dispos; 1982; 10(2):110-5. PubMed ID: 6124394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetaben versus clofibrate: comparison of toxicity and peroxisome proliferation in rats.
    Fort FL; Stein HH; Langenberg K; Lewkowski JP; Heyman IA; Kesterson JW
    Toxicology; 1983 Nov; 28(4):305-11. PubMed ID: 6606240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5,5'-Diphenyl-2-thiohydantoin (DPTH): an inducer of microsomal drug-metabolizing enzymes.
    Dalton C; Kamm JJ; Bartl P
    J Pharmacol Exp Ther; 1972 Sep; 182(3):491-9. PubMed ID: 5055407
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of nafenopin and clofibrate on uptake and utilization of labeled thymidine for DNA synthesis in rat liver and kidney.
    Seifert J; Mostecká H
    Carcinogenesis; 1988 Jan; 9(1):3-8. PubMed ID: 2446797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on hypolipidemic agents. III. Comparison of the hypolipidemic properties of 5-tridecylpyrazole-3-carboxylic acid and clofibrate.
    Seki K; Fukuda M; Isegawa J; Ohki M
    Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4103-9. PubMed ID: 6529804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.